Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
Provided By GlobeNewswire
Last update: Aug 15, 2023
Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain
Read more at globenewswire.com
